CA2479638C - Formulations de bromure de tiotropium cristallin anhydre en suspension dans du hfa - Google Patents
Formulations de bromure de tiotropium cristallin anhydre en suspension dans du hfa Download PDFInfo
- Publication number
- CA2479638C CA2479638C CA2479638A CA2479638A CA2479638C CA 2479638 C CA2479638 C CA 2479638C CA 2479638 A CA2479638 A CA 2479638A CA 2479638 A CA2479638 A CA 2479638A CA 2479638 C CA2479638 C CA 2479638C
- Authority
- CA
- Canada
- Prior art keywords
- hfa
- acid
- contain
- suspensions
- tiotropium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
Abstract
L'invention concerne des suspensions d'un anhydrate cristallin de bromure de (1.alpha.,2.beta.,4.beta.,5.alpha.,7.beta.)-7-[(hydroxydi-2-thiénylacétyl)oxy]-9,9-diméthyl-3-oxa-9-azoniatricyclo[3.3.1.0?2,4¿]nonane, qui contiennent des formulations de gaz propulseur.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10214264.5 | 2002-03-28 | ||
DE10214264A DE10214264A1 (de) | 2002-03-28 | 2002-03-28 | HFA-Suspensionsformulierungen eines Anhydrats |
PCT/EP2003/002899 WO2003082244A2 (fr) | 2002-03-28 | 2003-03-20 | Formulations de suspensions d'un anhydrate contenant un gaz propulseur hfa |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2479638A1 CA2479638A1 (fr) | 2003-10-09 |
CA2479638C true CA2479638C (fr) | 2011-01-04 |
Family
ID=28050990
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2479638A Expired - Fee Related CA2479638C (fr) | 2002-03-28 | 2003-03-20 | Formulations de bromure de tiotropium cristallin anhydre en suspension dans du hfa |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP1492498A2 (fr) |
JP (1) | JP5147158B2 (fr) |
KR (1) | KR101005717B1 (fr) |
CN (1) | CN1642525A (fr) |
AU (1) | AU2003221509B2 (fr) |
BR (1) | BR0308709A (fr) |
CA (1) | CA2479638C (fr) |
DE (1) | DE10214264A1 (fr) |
EA (1) | EA008610B1 (fr) |
EC (1) | ECSP045322A (fr) |
HR (1) | HRP20040890A2 (fr) |
IL (1) | IL163696A0 (fr) |
ME (1) | ME00246B (fr) |
MX (1) | MXPA04009338A (fr) |
NO (1) | NO20044004L (fr) |
NZ (1) | NZ536030A (fr) |
PL (1) | PL371295A1 (fr) |
RS (1) | RS52481B (fr) |
UA (1) | UA79776C2 (fr) |
WO (1) | WO2003082244A2 (fr) |
ZA (1) | ZA200405637B (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8324266B2 (en) | 2009-05-29 | 2012-12-04 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
US8808713B2 (en) | 2009-05-29 | 2014-08-19 | Pearl Thereapeutics, Inc. | Compositions for pulmonary delivery of long-acting β2 adrenergic receptor agonists and associated methods and systems |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2606549A1 (fr) * | 2005-05-02 | 2006-11-09 | Boehringer Ingelheim International Gmbh | Formes cristallines de bromure de tiotropium |
KR20080007656A (ko) * | 2005-05-02 | 2008-01-22 | 베링거 인겔하임 인터내셔날 게엠베하 | 티오트로피움 브로마이드의 신규한 결정질 형태 |
AU2015201037C1 (en) * | 2009-05-29 | 2017-07-27 | Pearl Therapeutics, Inc. | Respiratory delivery of active agents |
BR112015022784B1 (pt) | 2013-03-15 | 2023-02-14 | Pearl Therapeutics, Inc | Método de condicionamento de material cristalino micronizado e sistemas de condicionamento |
EP3515439B1 (fr) * | 2016-09-19 | 2021-12-15 | Mexichem Fluor S.A. de C.V. | Composition pharmaceutique comprenant du bromure de tiotropium |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3931041C2 (de) * | 1989-09-16 | 2000-04-06 | Boehringer Ingelheim Kg | Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
CN1150890C (zh) * | 1998-08-04 | 2004-05-26 | 杰格研究股份公司 | 药用气溶胶制剂 |
GB0009605D0 (en) * | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Medicaments |
GB0009606D0 (en) * | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Therapeutic combinations |
GB0009592D0 (en) * | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Respiratory combinations |
GB0009583D0 (en) * | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Respiratory formulations |
DE10111058A1 (de) * | 2001-03-08 | 2002-09-12 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und NK¶1¶-Rezeptor-Antagonisten |
CA2436537C (fr) * | 2000-10-31 | 2009-05-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Nouvelles compositions pharmaceutiques |
DE10113366A1 (de) * | 2001-03-20 | 2002-09-26 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Endothelinantagonisten |
-
2002
- 2002-03-28 DE DE10214264A patent/DE10214264A1/de not_active Withdrawn
-
2003
- 2003-03-20 ME MEP-2008-473A patent/ME00246B/fr unknown
- 2003-03-20 KR KR1020047015174A patent/KR101005717B1/ko active IP Right Grant
- 2003-03-20 CN CNA038072475A patent/CN1642525A/zh active Pending
- 2003-03-20 UA UA20041008758A patent/UA79776C2/uk unknown
- 2003-03-20 RS YU86004A patent/RS52481B/en unknown
- 2003-03-20 EA EA200401159A patent/EA008610B1/ru unknown
- 2003-03-20 IL IL16369603A patent/IL163696A0/xx unknown
- 2003-03-20 NZ NZ536030A patent/NZ536030A/en not_active IP Right Cessation
- 2003-03-20 BR BR0308709-3A patent/BR0308709A/pt active Pending
- 2003-03-20 MX MXPA04009338A patent/MXPA04009338A/es active IP Right Grant
- 2003-03-20 AU AU2003221509A patent/AU2003221509B2/en not_active Expired
- 2003-03-20 WO PCT/EP2003/002899 patent/WO2003082244A2/fr active Application Filing
- 2003-03-20 CA CA2479638A patent/CA2479638C/fr not_active Expired - Fee Related
- 2003-03-20 JP JP2003579782A patent/JP5147158B2/ja not_active Expired - Lifetime
- 2003-03-20 EP EP03717219A patent/EP1492498A2/fr not_active Withdrawn
- 2003-03-20 PL PL03371295A patent/PL371295A1/xx not_active Application Discontinuation
-
2004
- 2004-07-15 ZA ZA2004/05637A patent/ZA200405637B/en unknown
- 2004-09-23 NO NO20044004A patent/NO20044004L/no not_active Application Discontinuation
- 2004-09-27 HR HR20040890A patent/HRP20040890A2/hr not_active Application Discontinuation
- 2004-09-28 EC EC2004005322A patent/ECSP045322A/es unknown
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8324266B2 (en) | 2009-05-29 | 2012-12-04 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
US8703806B2 (en) | 2009-05-29 | 2014-04-22 | Pearl Therapeutics, Inc. | Compositions, methods and propellant-based systems for respiratory delivery of glycopyrrolate and one or more active agents |
US8808713B2 (en) | 2009-05-29 | 2014-08-19 | Pearl Thereapeutics, Inc. | Compositions for pulmonary delivery of long-acting β2 adrenergic receptor agonists and associated methods and systems |
US8815258B2 (en) | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
US9463161B2 (en) | 2009-05-29 | 2016-10-11 | Pearl Therapeutics, Inc. | Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems |
Also Published As
Publication number | Publication date |
---|---|
IL163696A0 (en) | 2005-12-18 |
AU2003221509A1 (en) | 2003-10-13 |
BR0308709A (pt) | 2005-01-04 |
MXPA04009338A (es) | 2005-01-25 |
NO20044004L (no) | 2004-10-05 |
UA79776C2 (en) | 2007-07-25 |
EP1492498A2 (fr) | 2005-01-05 |
NZ536030A (en) | 2006-07-28 |
KR20040098022A (ko) | 2004-11-18 |
AU2003221509B2 (en) | 2008-01-24 |
JP2005527550A (ja) | 2005-09-15 |
WO2003082244A2 (fr) | 2003-10-09 |
EA008610B1 (ru) | 2007-06-29 |
MEP47308A (en) | 2011-02-10 |
KR101005717B1 (ko) | 2011-01-05 |
JP5147158B2 (ja) | 2013-02-20 |
RS52481B (en) | 2013-02-28 |
EA200401159A1 (ru) | 2005-04-28 |
ZA200405637B (en) | 2005-07-27 |
YU86004A (sh) | 2006-08-17 |
DE10214264A1 (de) | 2003-10-16 |
CN1642525A (zh) | 2005-07-20 |
WO2003082244A3 (fr) | 2004-02-05 |
CA2479638A1 (fr) | 2003-10-09 |
HRP20040890A2 (en) | 2005-06-30 |
PL371295A1 (en) | 2005-06-13 |
ECSP045322A (es) | 2005-01-28 |
ME00246B (fr) | 2011-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7736627B2 (en) | HFA suspension formulations containing an anticholinergic | |
CA2450961C (fr) | Substance anticholinergique cristalline, procedes de production et son utilisation pour la production de composition pharmaceutique | |
MXPA03003221A (es) | Monohidrato cristalino, procedmiento para su preparacion y su uso para la preparacion de un medicamento. | |
CA2544352C (fr) | Anhydrate cristallin a effet anticholinergique | |
ZA200602343B (en) | Novel tiotropium salts, methods for the production thereof, and pharmaceutical formulations containing the same | |
ZA200602342B (en) | Method for producing tiotropium salts, tiotropium salts and pharmaceutical formulations, containing the same | |
CA2479638C (fr) | Formulations de bromure de tiotropium cristallin anhydre en suspension dans du hfa | |
CA2479640C (fr) | Formulations de hfa en suspensions contenant un anticholinergique | |
US7244415B2 (en) | HFA suspension formulations of an anhydrate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20220301 |
|
MKLA | Lapsed |
Effective date: 20200831 |